Omeros Corporation (OMER) announced on Wednesday that the U.S. FDA approved its lead asset, narsoplimab-wuug, as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem cell transplantation. The treatment branded as Yartemlea is expected to be ...